Patent ID: 8822416

Claim:
A topical analgesic composition for use on a significant open skin wound, said composition comprising: about 40.0 mg/mL to 50.0 mg/mL of lignocaine HCl as a first local anesthetic agent having a rapid onset of action and present in an amount effective to anesthetize the open skin wound; 0 mg/mL to about 5.0 mg/mL bupivacaine HCl as a second local anesthetic agent having a long duration of action; about 36.0 μg/mL to 45.0 μg/mL adrenaline tartrate as a vasoconstrictor present in an amount effective to reduce bleeding from the open skin wound and to decrease the rate of vascular absorption of the local anesthetic agents so as to reduce the risk of systemic toxicity; up to about 5.0 mg/mL cetrimide as an antiseptic agent in an amount effective to minimize infection of the open skin wound; about 1.5 mg/mL sodium metabisulfite as an antioxidant; and about 100 mg/mL non-crystallizing liquid sorbitol (70%) and about 5.0 mg/mL hydroxy cellulose as a carrier applicable to the open skin wound in a fluid form, wherein said carrier: adheres to the open skin wound; forms a long-lasting viscous barrier over the open skin wound, that is capable of remaining firmly adhered to the open skin wound until the open skin wound has naturally sealed or pain due to the open skin wound has otherwise abated by way of a natural healing process; promotes and prolongs contact of the anesthetic agents and the vasoconstrictor with the open skin wound; and aids in healing of the open skin wound by minimizing or preventing water loss from the open skin wound and by acting as a barrier against microbial contamination, wherein the composition provides an analgesic effect beyond that attributable to the anesthetic agents alone whilst the barrier covers the skin wound, and wherein said long-lasting viscous barrier is capable of remaining intact over the open skin wound for at least 4 hours and is in a form selected from the group consisting of a gel and spray-solution.